Zydus Lifesciences Limited (NSE:ZYDUSLIFE) announced on 23 July 2026 that it has received regulatory approval to conduct a Phase III clinical trial of Desidustat for patients with sickle cell disease. The trial, to be conducted in collaboration with the Indian Council of Medical Research (ICMR), will enrol 164 patients and run for 203 days to evaluate the efficacy and safety of the oral tablet formulation in treating anaemia associated with the disease.
Key Highlights
- Zydus received approval to initiate a Phase III double-blind, randomised, placebo-controlled, multicentre clinical trial of Desidustat for sickle cell disease with 164 enrolled patients.
- The preceding Phase II proof-of-concept trial, completed jointly with ICMR, met its primary endpoint and demonstrated a favourable safety profile with only minimal adverse events reported across three dose levels (50 mg, 100 mg, and 150 mg).
- Desidustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor discovered and developed at Zydus research laboratories and already approved by the Drug Controller General of India in March 2022 for anaemia in chronic kidney disease patients.
- The US FDA granted Orphan Drug Designation to Desidustat for treating sickle cell disease and beta-thalassemia, a classification that provides accelerated regulatory pathways and market exclusivity incentives.
- Sickle cell disease affects an estimated 20 million people in India according to National Health Mission data, with approximately 50,000 children born annually with the condition, primarily affecting tribal populations.
- The Phase III trial will be conducted over 203 days and will evaluate the drug's ability to improve haemoglobin levels and overall efficacy in anaemia management in sickle cell disease patients.
- Desidustat represents a potential first-in-class therapeutic option for sickle cell disease, addressing an unmet medical need as existing treatments such as hydroxyurea have limited accessibility and inconsistent effectiveness.
About the Company
Zydus Lifesciences Limited (NSE:ZYDUSLIFE), headquartered in Ahmedabad, is an innovation-led global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies across vaccines, therapeutics, biologicals, and new chemical entities. The company employs over 30,000 people worldwide, including 1,500 scientists engaged in research and development. Desidustat, the compound at the centre of this trial, was discovered and developed at Zydus' own research and development laboratories. The company received approval from the Drug Controller General of India in March 2022 for Desidustat's use in treating anaemia in patients with chronic kidney disease, both those on dialysis and those not on dialysis. In March 2026, the National Medical Products Administration of China also approved Desidustat for treatment of renal anaemia in chronic kidney disease patients, expanding its clinical footprint internationally.
Announcement in Detail
Zydus Lifesciences and the Indian Council of Medical Research have completed a Phase II proof-of-concept trial of Desidustat in sickle cell disease patients. This study, co-funded and co-monitored by ICMR-INTENT (Indian National Clinical Trial and Education Network, Clinical Studies and Trial Unit), met its primary endpoint. The trial found that Desidustat was well tolerated up to the 150 mg dose, with only minimal adverse events reported. Across all three dose cohorts (50 mg, 100 mg, and 150 mg), the drug demonstrated a favourable safety and tolerability profile. The reported treatment-emergent adverse events were limited to nasopharyngitis, polyarthritis, and headache, all of mild severity, with no serious adverse events recorded during the study period. The trial demonstrated a promising trend towards improvement in haemoglobin levels and higher responder rates compared to placebo in patients with sickle cell disease.
Building on this Phase II success, the company has now received regulatory approval to proceed with Phase III testing. The Phase III trial will be a double-blind, randomised, placebo-controlled, parallel, multicentre study designed to evaluate the efficacy and safety of Desidustat oral tablets for treating anaemia in sickle cell disease patients. The trial will enrol 164 patients with a confirmed sickle cell disease diagnosis and will run for 203 days. This larger, more rigorous study design is a standard requirement to generate the clinical evidence necessary for regulatory approval of new therapeutics. Desidustat, as a hypoxia-inducible factor prolyl hydroxylase inhibitor, works by stimulating endogenous erythropoietin production through a mechanism similar to the body's natural physiological response to low oxygen levels.
The regulatory environment has been supportive of this development pathway. The US FDA previously granted Orphan Drug Designation to Desidustat for two rare blood disorders: sickle cell disease and beta-thalassemia. Orphan Drug Designation provides several regulatory advantages, including accelerated approval pathways, extended market exclusivity, and reduced application fees, thereby incentivising the development of therapies for rare conditions with limited commercial markets. In India, sickle cell disease represents a significant public health concern, with National Health Mission estimates indicating that nearly 20 million people live with the condition and approximately 50,000 children are born with sickle cell anaemia each year, particularly among tribal populations where the disease prevalence is higher.
Impact on Investors
Investors will note that regulatory approval for Phase III trials in sickle cell disease represents a material expansion of Desidustat's clinical development pipeline and therapeutic addressable market. The drug has already achieved regulatory approval in two major markets (India and China) for chronic kidney disease-related anaemia, establishing both manufacturing scale and regulatory track record. The Phase III trial approval signals that regulatory authorities view the drug's safety and efficacy data as sufficiently strong to warrant advancement to the final stage of clinical testing required for market approval. A successful Phase III outcome could potentially expand the drug's approved indications and open a new therapeutic category, particularly significant given that sickle cell disease affects a large patient population in India with limited effective treatment options.
The filing shows that completion of Phase III trials typically requires 12 to 24 months, meaning regulatory decisions on this indication would likely emerge in the 2027 to 2028 timeframe. Shareholders will observe that Orphan Drug Designation provides intellectual property and market exclusivity protections once approved, reducing future competitive pressure in this indication. However, investors should note that Phase III trials carry inherent clinical and regulatory risk; unforeseen safety signals or efficacy shortfalls could delay or prevent regulatory approval. The disclosed terms and trial structure indicate that Zydus is investing significant resources into this development, which could impact near-term research and development expenses on the consolidated profit and loss statement. The collaborative structure with ICMR, a government institution, may also facilitate trial recruitment and regulatory engagement in India, potentially accelerating the approval timeline compared to standalone company-sponsored trials.
Sector / Market Context
India's pharmaceutical sector has increasingly focused on developing therapies for rare and neglected diseases, supported by policy initiatives and regulatory incentives such as Orphan Drug Designation. According to data from the Department of Health Research and ICMR, India accounts for approximately 50% of global sickle cell disease burden, with prevalence concentrated in specific tribal and ethnic populations. Current standard-of-care treatments include hydroxyurea and blood transfusions, both of which face significant limitations in terms of accessibility, side effects, and long-term tolerability. The unmet medical need in this space is therefore substantial, and new therapeutic options that are oral, better tolerated, and effective could command meaningful market uptake. Global pharmaceutical companies have increasingly pursued HIF-PHD (hypoxia-inducible factor prolyl hydroxylase) inhibitor programmes for anaemia-related indications, and Desidustat's early-stage positioning in this drug class aligns with broader industry trends. The Phase III approval also reflects India's emerging role as a site for late-stage clinical trials, particularly for conditions with high disease burden in the Indian population, strengthening the country's clinical research infrastructure.